177 related articles for article (PubMed ID: 23873310)
1. The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis.
Yang P; Du CW; Kwan M; Liang SX; Zhang GJ
Sci Rep; 2013; 3():2246. PubMed ID: 23873310
[TBL] [Abstract][Full Text] [Related]
2. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
3. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer.
Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH
Oncology; 2004; 66(6):429-38. PubMed ID: 15452371
[TBL] [Abstract][Full Text] [Related]
4. Expression of c-erbB-2 and p53 in breast carcinoma patients: comparison with traditional prognostic factors and survival.
Gurkan A; Erdogan G; Erdogan O; Pestereli E; Ogus M; Karaveli S; Colak T
J Int Med Res; 2004; 32(5):455-64. PubMed ID: 15458277
[TBL] [Abstract][Full Text] [Related]
5. The effect of immunohistochemically detected p53 accumulation in prognosis of breast cancer; A retrospective survey of outcome.
Sadighi S; Zokaasadi M; Kasaeian A; Maghsudi S; Jahanzad I; Kamranzadeh Fumani H
PLoS One; 2017; 12(8):e0182444. PubMed ID: 28771563
[TBL] [Abstract][Full Text] [Related]
6. Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort.
Levesque MA; Yu H; Clark GM; Diamandis EP
J Clin Oncol; 1998 Aug; 16(8):2641-50. PubMed ID: 9704714
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer.
Ren J; Chen QC; Jin F; Wu HZ; He M; Zhao L; Yu ZJ; Yao WF; Mi XY; Wang EH; Wei MJ
Int J Clin Exp Pathol; 2014; 7(9):5595-608. PubMed ID: 25337201
[TBL] [Abstract][Full Text] [Related]
8. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
[TBL] [Abstract][Full Text] [Related]
9. Hierarchical investigating the predictive value of p53, COX2, EGFR, nm23 in the post-operative patients with colorectal carcinoma.
Du P; Xu B; Zhang D; Shao Y; Zheng X; Li X; Xiong Y; Wu C; Jiang J
Oncotarget; 2017 Jan; 8(1):954-966. PubMed ID: 27888614
[TBL] [Abstract][Full Text] [Related]
10. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
Shao ZM; Wu J; Shen ZZ; Nguyen M
Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
12. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis.
Pellikainen MJ; Pekola TT; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
J Clin Pathol; 2003 Mar; 56(3):214-20. PubMed ID: 12610102
[TBL] [Abstract][Full Text] [Related]
13. Relationship of p53 expression with clinicopathological variables and disease outcome: a prospective study on 315 consecutive breast carcinoma patients.
Aziz SA; Pervez S; Khan S; Kayani N; Rahbar MH
Malays J Pathol; 2001 Dec; 23(2):65-71. PubMed ID: 12166594
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.
Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Chikhlikar PR; Ghosh N; Trivedi TI
Ann Surg Oncol; 2000 May; 7(4):305-11. PubMed ID: 10819372
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis and p53 protein expression in breast cancer: prognostic roles and interrelationships.
Tas F; Yavuz E; Aydiner A; Saip P; Disci R; Iplikci A; Topuz E
Am J Clin Oncol; 2000 Dec; 23(6):546-53. PubMed ID: 11202793
[TBL] [Abstract][Full Text] [Related]
18. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.
Nishimura R; Osako T; Okumura Y; Tashima R; Toyozumi Y; Arima N
World J Surg Oncol; 2011 Oct; 9():131. PubMed ID: 22004841
[TBL] [Abstract][Full Text] [Related]
19. Metastatic site and p53 primary tumor expression in previously untreated stage IV breast cancer patients.
Paradiso A; Tommasi S; Barletta A; Leone B; Lacava J; Vellejo C; Labriola A; Marzullo F; Altieri R; Schittulli F; De Lena M
Anticancer Res; 1999; 19(5C):4523-8. PubMed ID: 10650804
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
